Proglucagon-derived peptides: mechanisms of action and therapeutic potential.
about
New perspectives on exploitation of incretin peptides for the treatment of diabetes and related disordersRelationship between gut hormones and glucose homeostasis after bariatric surgeryDietary Polyphenols Promote Growth of the Gut Bacterium Akkermansia muciniphila and Attenuate High-Fat Diet-Induced Metabolic Syndrome.Glucagon-like peptide-1 modulates neurally evoked mucosal chloride secretion in guinea pig small intestine in vitro.Irinotecan-induced mucositis: the interactions and potential role of GLP-2 analogues.Review article: glucagon-like peptide 2--current applications and future directions.Paying the price for eating ice cream: is excessive GLP-1 signaling in the brain the culprit?Glucagon-like peptide 1 based therapy for type 2 diabetes.Enteral nutrients potentiate the intestinotrophic action of glucagon-like peptide-2 in association with increased insulin-like growth factor-I responses in rats.Overnutrition stimulates intestinal epithelium proliferation through β-catenin signaling in obese mice.Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects.Type 2 diabetes mellitus: a possible surgically reversible intestinal dysfunction.Review article: a comparison of glucagon-like peptides 1 and 2.Gut microbiota and GLP-1.Gut feedback mechanisms and food intake: a physiological approach to slow carbohydrate bioavailability.Colonic GLP-2 is not sufficient to promote jejunal adaptation in a PN-dependent rat model of human short bowel syndrome.Exogenous glucagon-like peptide-2 (GLP-2) augments GLP-2 receptor mRNA and maintains proglucagon mRNA levels in resected rats.A novel DPP IV-resistant C-terminally extended glucagon analogue exhibits weight-lowering and diabetes-protective effects in high-fat-fed mice mediated through glucagon and GLP-1 receptor activation.Adding prandial GLP-1 receptor agonists to basal insulin: a promising option for type 2 diabetes therapy.The role of glucagon-like peptide-2 on apoptosis, cell proliferation, and oxidant-antioxidant system at a mouse model of intestinal injury induced by tumor necrosis factor-alpha/actinomycin D.GLP-2 rapidly activates divergent intracellular signaling pathways involved in intestinal cell survival and proliferation in neonatal piglets.Carriers of the TCF7L2 rs7903146 TT genotype have elevated levels of plasma glucose, serum proinsulin and plasma gastric inhibitory polypeptide (GIP) during a meal testThe alpha cell expresses glucagon-like peptide-2 receptors and glucagon-like peptide-2 stimulates glucagon secretion from the rat pancreasVagal afferents are essential for maximal resection-induced intestinal adaptive growth in orally fed rats
P2860
Q26777654-C74D475E-FE59-4250-93A6-2917D21F15D2Q27022123-2C748920-7FEB-42AE-B2E0-17CD2FE8CACAQ35595578-CACC2A74-25DE-4C2F-A03C-3D02E737F566Q35780892-DD27011D-D4D4-4646-97D0-679E2037278AQ36171894-6726DFF9-8402-4993-ABF5-202636761506Q36705323-7837266A-AB2B-40FF-8C1C-FA48737EDAF8Q36972727-76EDCBFF-631B-4ED2-9758-3DD2057B760EQ37134320-94731C19-F71D-44FF-8179-9AD8F2E029A5Q37200132-7FB1A5C1-68CD-4B18-B2CB-F44673452568Q37251157-2885FF61-E16D-4715-8DB2-CFC8D7823D4CQ37760515-AB4520F4-847C-4C71-B812-EA15F556A8B7Q37957560-B5D1D5AC-5187-47DC-80BA-4C41C53A1EFCQ38057350-FC031D13-A4FA-4FCE-BE03-6AEB141C4311Q38208787-7058A6EE-D8F7-483E-BFD1-C0E9F576E813Q38357251-DA38C790-A631-46F6-AA1F-006629946090Q39974467-26AD98FE-CACC-4A46-9E1A-9F3E22FEA83EQ39974508-7567EC7C-DC38-4434-BE5F-A73B7E909699Q47578474-C70393F5-8456-4D1C-AF06-5F1DFC6AF446Q52536332-EEA8AC06-4FC1-4D93-A43A-09E0F1F5527CQ53283425-02581762-8CD6-4212-AD4E-57D9353890A8Q54211552-8D9AE550-9CF7-47D1-8201-3964DD8F95E3Q57402000-D3347C7A-F855-4F92-9E6F-B9F6AF957163Q58448384-194BCF87-16F6-4FA7-87F6-2C276D69C9FEQ58448497-4D4DAF2B-797E-4DE0-9787-901FFABF0958
P2860
Proglucagon-derived peptides: mechanisms of action and therapeutic potential.
description
2005 nî lūn-bûn
@nan
2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Proglucagon-derived peptides: mechanisms of action and therapeutic potential.
@ast
Proglucagon-derived peptides: mechanisms of action and therapeutic potential.
@en
Proglucagon-derived peptides: mechanisms of action and therapeutic potential.
@nl
type
label
Proglucagon-derived peptides: mechanisms of action and therapeutic potential.
@ast
Proglucagon-derived peptides: mechanisms of action and therapeutic potential.
@en
Proglucagon-derived peptides: mechanisms of action and therapeutic potential.
@nl
prefLabel
Proglucagon-derived peptides: mechanisms of action and therapeutic potential.
@ast
Proglucagon-derived peptides: mechanisms of action and therapeutic potential.
@en
Proglucagon-derived peptides: mechanisms of action and therapeutic potential.
@nl
P2860
P1433
P1476
Proglucagon-derived peptides: mechanisms of action and therapeutic potential.
@en
P2093
Elaine M Sinclair
P2860
P304
P356
10.1152/PHYSIOL.00030.2005
P577
2005-10-01T00:00:00Z